Suppr超能文献

镰状细胞病患者红细胞同种免疫的早期发生。

Early occurrence of red blood cell alloimmunization in patients with sickle cell disease.

机构信息

Department of Pediatric Hematology, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands.

Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands.

出版信息

Am J Hematol. 2016 Aug;91(8):763-9. doi: 10.1002/ajh.24397. Epub 2016 May 24.

Abstract

Red blood cell (RBC) alloimmunization is a major complication of transfusion therapy in sickle cell disease (SCD). Identification of high-risk patients is hampered by lack of studies that take the cumulative transfusion exposure into account. In this retrospective cohort study among previously non-transfused SCD patients in the Netherlands, we aimed to elucidate the association between the cumulative transfusion exposure, first alloimmunization and independent risk factors. A total of 245 patients received 11 952 RBC units. Alloimmunization occurred in 43 patients (18%), half of them formed their first alloantibody before the 8th unit. In patients with exposure to non-extended matched transfusions (ABO and RhD) the cumulative alloimmunization risk increased up to 35% after 60 transfused units. This was significantly higher compared to a general transfused population (HR 6.6, CI 4.2-10.6). Receiving the first transfusion after the age of 5 was an independent risk factor for alloimmunization (HR 2.3, CI 1.0-5.1). Incidental, episodic transfusions in comparison to chronic scheme transfusions (HR 2.3, CI 0.9-6.0), and exposure to non-extended matched units in comparison to extended matching (HR 2.0, CI 0.9-4.6) seemed to confer a higher alloimmunization risk. The majority of first alloantibodies are formed after minor transfusion exposure, substantiating suggestions of a responder phenotype in SCD and stressing the need for risk factor identification. In this study, older age at first transfusion, episodic transfusions and non-extended matched transfusions appeared to be risk factors for alloimmunization. Am. J. Hematol. 91:763-769, 2016. © 2016 Wiley Periodicals, Inc.

摘要

红细胞(RBC)同种免疫是镰状细胞病(SCD)输血治疗的主要并发症。由于缺乏考虑累积输血暴露的研究,高危患者的识别受到阻碍。在荷兰,这项针对以前未接受过输血的 SCD 患者的回顾性队列研究中,我们旨在阐明累积输血暴露、首次同种免疫和独立危险因素之间的关系。共有 245 名患者接受了 11952 个 RBC 单位。43 名患者(18%)发生了同种免疫,其中一半在第 8 个单位之前就形成了他们的第一个同种抗体。在接受非扩展匹配输血(ABO 和 RhD)的患者中,在输注 60 个单位后,累积同种免疫风险增加到 35%。这明显高于一般输血人群(HR6.6,CI4.2-10.6)。在 5 岁以后接受首次输血是同种免疫的独立危险因素(HR2.3,CI1.0-5.1)。与慢性方案输血相比,偶然、间歇性输血(HR2.3,CI0.9-6.0)和非扩展匹配单位暴露与扩展匹配相比(HR2.0,CI0.9-4.6)似乎会带来更高的同种免疫风险。大多数首次同种抗体是在少量输血暴露后形成的,这证实了 SCD 中存在应答者表型的说法,并强调了识别危险因素的必要性。在这项研究中,首次输血年龄较大、间歇性输血和非扩展匹配输血似乎是同种免疫的危险因素。美国血液学杂志 91:763-769,2016。©2016 年 Wiley 期刊,Inc.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验